OKYO Pharma reports $20.6 million cash position ahead of Phase 3 NEPTUNE trial

The annual report for the fiscal year ended March 31, 2026 said roughly $25 million was raised during the year, bolstering funding for the company’s planned global late-stage study.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.